Attovia Therapeutics, Inc.

Filing Date

Aug 28, 2026

Transaction Date

Aug 5, 2026

Accession Number

0001866174-26-000011

Form Type

4

Net Trading Amount

$8.0M

Footnotes

1. (F1)The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
2. (F2)These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer.
3. (F3)GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4.
4. (F4)The previous report on Form 3 reflected an administrative error with respect to the number of shares of common stock issuable upon conversion of the Preferred Stock, which is corrected in this Form 4.
5. (F5)Each share of Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock") automatically converted into shares of the Issuer's common stock on a 9.29-for-1 basis upon the closing of the Issuer's initial public offering (the "IPO") on August 6, 2026 without payment of consideration. The Preferred Stock has no expiration date.
6. (F6)The Reporting Person is a managing director of GS&Co, a subsidiary of The Goldman Sachs Group Inc. ("GS Group"). GS Group is the direct owner of GS&Co and an indirect owner of Goldman Sachs Asset Management, L.P. ("GSAM LP"). GS&Co is the manager of Broad Street Principal Investments L.L.C. ("BSPI") which directly holds 96,190 shares of common stock purchased in the IPO and 468,565 shares of common stock converted from 3,497,806 shares of Series B Preferred Stock and 855,179 shares of Series C Preferred Stock of the Issuer. GSAM LP is the investment manager of WSLS Offshore Investments, SLP ("WSLS Offshore") which directly holds 131,283 shares of common stock purchased in the IPO and 639,518 shares of common stock converted from 4,773,948 shares of Series B Preferred Stock and 1,167,182 shares of Series C Preferred Stock of the Issuer,... (continued in footnote 7)
7. (F7)(continued from footnote 6)... West Street Life Sciences I, L.P. ("WSLS I") which directly holds 137,708 shares of common stock purchased in the IPO and 670,812 shares of common stock converted from 5,007,564 shares of Series B Preferred Stock and 1,224,299 shares of Series C Preferred Stock of the Issuer, WSLS Emp Offshore Investments, L.P. ("WSLS Emp Offshore") which directly holds 36,927 shares of common stock purchased in the IPO and 179,879 shares of common stock converted from 1,342,794 shares of Series B Preferred Stock and 328,300 shares of Series C Preferred Stock of the Issuer, and WSLS Emp Onshore Investments, L.P. ("WSLS Emp Onshore") which directly holds 97,892 shares of common stock purchased in the IPO and 476,858 shares of common stock converted from 3,559,718 shares of Series B Preferred Stock and 870,315 shares of Series C Preferred Stock of the Issuer,... (continued in footnote 8)
8. (F8)(continued from footnote 7)... GS&Co is a direct subsidiary of GS Group and is the manager of BSPI. WSLS Offshore, WSLS I, WSLS Emp Offshore, and WSLS Emp Onshore are investment vehicles managed by GSAM LP, an indirect subsidiary of GS Group.